Patents by Inventor Thomas G. McCauley
Thomas G. McCauley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160367586Abstract: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under the brand Xalatan™ and Compound A.Type: ApplicationFiled: May 18, 2016Publication date: December 22, 2016Inventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY, Rudolf A. BAUMGARTNER
-
Patent number: 9370530Abstract: The present invention is directed to a composition or a kit comprising a combination of a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit.Type: GrantFiled: October 17, 2014Date of Patent: June 21, 2016Assignee: Inotek Pharmaceuticals CorporationInventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Rudolf A. Baumgartner
-
Publication number: 20160158268Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).Type: ApplicationFiled: February 16, 2016Publication date: June 9, 2016Inventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY, Prakash JAGTAP
-
Patent number: 9289383Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).Type: GrantFiled: November 24, 2014Date of Patent: March 22, 2016Assignee: Inotek Pharmaceuticals CorporationInventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Prakash Jagtap
-
Publication number: 20150080330Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).Type: ApplicationFiled: November 24, 2014Publication date: March 19, 2015Inventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY, Prakash JAGTAP
-
Publication number: 20150038448Abstract: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under the brand Xalatan™ and Compound A.Type: ApplicationFiled: October 17, 2014Publication date: February 5, 2015Inventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY, Rudolf A. BAUMGARTNER
-
Patent number: 8895530Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).Type: GrantFiled: June 4, 2013Date of Patent: November 25, 2014Assignee: Inotek Pharmaceuticals CorporationInventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Prakash Jagtap
-
Patent number: 8877732Abstract: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit.Type: GrantFiled: January 11, 2011Date of Patent: November 4, 2014Assignee: Inotek Pharmaceuticals CorporationInventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Rudolf A. Baumgartner
-
Publication number: 20140018314Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).Type: ApplicationFiled: June 4, 2013Publication date: January 16, 2014Applicant: Inotek Pharmaceuticals CorporationInventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY, Prakash JAGTAP
-
Patent number: 8476247Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).Type: GrantFiled: March 25, 2011Date of Patent: July 2, 2013Assignee: Inotek Pharmaceuticals CorporationInventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Prakash Jagtap
-
Patent number: 8455457Abstract: Provided herein is a pharmaceutical composition or a kit comprising a combination of a non-selective beta-adrenergic receptor blocker and an adenosine A1 receptor agonist. Also provided herein is a method of reducing intraocular pressure (IOP) in a subject using such a combination or kit. In a particular embodiment, provided herein is a combination of timolol marketed under the brand Timoptic™ and Compound A.Type: GrantFiled: March 18, 2011Date of Patent: June 4, 2013Assignee: Inotek Pharmaceuticals CorporationInventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley
-
Patent number: 8440639Abstract: Provided herein is a pharmaceutical composition or a kit comprising a combination of a carbonic anhydrase inhibitor analog and an adenosine A1 receptor agonist. Also provided herein is a method of reducing intraocular pressure (IOP) in a subject using such a combination or kit. In a particular embodiment, provided herein is a combination of dorzolamide marketed under the brand Trusopt™ and Compound A.Type: GrantFiled: March 18, 2011Date of Patent: May 14, 2013Assignee: Inotek Pharmaceuticals CorporationInventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley
-
Publication number: 20110251151Abstract: Provided herein is a pharmaceutical composition or a kit comprising a combination of a non-selective beta-adrenergic receptor blocker and an adenosine A1 receptor agonist. Also provided herein is a method of reducing intraocular pressure (IOP) in a subject using such a combination or kit. In a particular embodiment, provided herein is a combination of timolol marketed under the brand Timoptic™ and Compound A.Type: ApplicationFiled: March 18, 2011Publication date: October 13, 2011Applicant: INOTEK PHARMACEUTICALS CORPORATIONInventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY
-
Publication number: 20110245193Abstract: Provided herein is a pharmaceutical composition or a kit comprising a combination of a carbonic anhydrase inhibitor analog and an adenosine A1 receptor agonist. Also provided herein is a method of reducing intraocular pressure (IOP) in a subject using such a combination or kit. In a particular embodiment, provided herein is a combination of dorzolamide marketed under the brand Trusopt™ and Compound A.Type: ApplicationFiled: March 18, 2011Publication date: October 6, 2011Applicant: INOTEK PHARMACEUTICALS CORPORATIONInventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY
-
Publication number: 20110245195Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).Type: ApplicationFiled: March 25, 2011Publication date: October 6, 2011Applicant: INOTEK PHARMACEUTICALS CORPORATIONInventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY, Prakash JAGTAP
-
Publication number: 20110172177Abstract: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under the brand Xalatan™ and Compound A.Type: ApplicationFiled: January 11, 2011Publication date: July 14, 2011Applicant: INOTEK PHARMACEUTICALS CORPORATIONInventors: Norman N. KIM, William K. MCVICAR, Thomas G. McCAULEY, Rudolf A. BAUMGARTNER
-
Patent number: 7125660Abstract: Methods for engineering a nucleic acid sensor molecule are provided. Biosensors comprise a plurality of nucleic acid sensor molecules labeled with a first signaling moiety and a second signaling moiety. The nucleic acid sensor molecules recognizes target molecules which do not naturally bind to DNA. Binding of a target molecule to the sensor molecules triggers a change in the proximity of the signaling moieties which leads to a change in the optical properties of the nucleic acid sensor molecules on the biosensor. Reagents and systems for performing the method are also provided. The method is useful in diagnostic applications and drug optimization.Type: GrantFiled: August 9, 2002Date of Patent: October 24, 2006Assignee: Archemix Corp.Inventors: Martin Stanton, David Epstein, Nobuko Hamaguchi, Markus Kurz, Tony Keefe, Charles Wilson, Dilara Grate, Kristin A. Marshall, Thomas G. McCauley, Jeffrey C. Kurz
-
Publication number: 20040219523Abstract: Methods for engineering a nucleic acid sensor molecule are provided. Biosensors comprise a plurality of nucleic acid sensor molecules labeled with a first signaling moiety and a second signaling moiety. The nucleic acid sensor molecules recognizes target molecules which do not naturally bind to DNA. Binding of a target molecule to the sensor molecules triggers a change in the proximity of the signaling moieties which leads to a change in the optical properties of the nucleic acid sensor molecules on the biosensor. Reagents and systems for performing the method are also provided. The method is useful in diagnostic applications and drug optimization.Type: ApplicationFiled: August 9, 2002Publication date: November 4, 2004Inventors: Martin Stanton, David Epstein, Nobuko Hamaguchi, Markus Kurz, Tony Keefe, Charles Wilson, Dilara Grate, Kristin A. Marshall, Thomas G. McCauley, Jeffrey C. Kurz
-
Patent number: 6592839Abstract: A method for controlling the crystallite size and growth rate of plasma-deposited diamond films. A plasma is established at a pressure in excess of about 55 Torr with controlled concentrations of hydrogen up to about 98% by volume, of unsubstituted hydrocarbons up to about 3% by volume and an inert gas of one or more of the noble gases and nitrogen up to about 98% by volume. The volume ratio of inert gas to hydrogen is preferably maintained at greater than about 4, to deposit a diamond film on a suitable substrate. The diamond film is deposited with a predetermined crystallite size and at a predetermined growth rate.Type: GrantFiled: February 23, 1999Date of Patent: July 15, 2003Assignee: The University of ChicagoInventors: Dieter M. Gruen, Thomas G. McCauley, Dan Zhou, Alan R. Krauss
-
Publication number: 20020114756Abstract: A method for controlling the crystallite size and growth rate of plasma-deposited diamond films. A plasma is established at a pressure in excess of about 55 Torr with controlled concentrations of hydrogen up to about 98% by volume, of unsubstituted hydrocarbons up to about 3% by volume and an inert gas of one or more of the noble gases and nitrogen up to about 98% by volume. The volume ratio of inert gas to hydrogen is preferably maintained at greater than about 4, to deposit a diamond film on a suitable substrate. The diamond film is deposited with a predetermined crystallite size and at a predetermined growth rate.Type: ApplicationFiled: February 23, 1999Publication date: August 22, 2002Inventors: DIETER M. GRUEN, THOMAS G. MCCAULEY, DAN ZHOU, ALAN R. KRAUSS